APA

van Ojik H. H., Bevaart L., Dahle C. E., Bakker A., Jansen M. J. H., van Vugt M. J., van de Winkel J. G. J. & Weiner G. J. (20031106). CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. : Cancer research.

Chicago

van Ojik Heidi H, Bevaart Lisette, Dahle Christopher E, Bakker Annie, Jansen Marco J H, van Vugt Martine J, van de Winkel Jan G J and Weiner George J. 20031106. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. : Cancer research.

Harvard

van Ojik H. H., Bevaart L., Dahle C. E., Bakker A., Jansen M. J. H., van Vugt M. J., van de Winkel J. G. J. and Weiner G. J. (20031106). CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. : Cancer research.

MLA

van Ojik Heidi H, Bevaart Lisette, Dahle Christopher E, Bakker Annie, Jansen Marco J H, van Vugt Martine J, van de Winkel Jan G J and Weiner George J. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. : Cancer research. 20031106.